Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

1.

Increased cerebrospinal fluid F2-isoprostanes are associated with aging and latent Alzheimer's disease as identified by biomarkers.

Montine TJ, Peskind ER, Quinn JF, Wilson AM, Montine KS, Galasko D.

Neuromolecular Med. 2011 Mar;13(1):37-43. doi: 10.1007/s12017-010-8126-6. Epub 2010 Jul 15.

PMID:
20632131
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Cerebrospinal fluid markers for Alzheimer's disease in a cognitively healthy cohort of young and old adults.

Paternicò D, Galluzzi S, Drago V, Bocchio-Chiavetto L, Zanardini R, Pedrini L, Baronio M, Amicucci G, Frisoni GB.

Alzheimers Dement. 2012 Nov;8(6):520-7. doi: 10.1016/j.jalz.2011.10.003. Epub 2012 Jun 6.

PMID:
22677492
[PubMed - indexed for MEDLINE]
3.

Oxidative stress and amyloid-beta pathology in normal individuals with a maternal history of Alzheimer's.

Mosconi L, Glodzik L, Mistur R, McHugh P, Rich KE, Javier E, Williams S, Pirraglia E, De Santi S, Mehta PD, Zinkowski R, Blennow K, Pratico D, de Leon MJ.

Biol Psychiatry. 2010 Nov 15;68(10):913-21. doi: 10.1016/j.biopsych.2010.07.011.

PMID:
20817151
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.

Kang JH, Vanderstichele H, Trojanowski JQ, Shaw LM.

Methods. 2012 Apr;56(4):484-93. doi: 10.1016/j.ymeth.2012.03.023. Epub 2012 Apr 6. Review.

PMID:
22503777
[PubMed - indexed for MEDLINE]
5.

Cerebrospinal fluid abeta42, tau, and f2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls.

Montine TJ, Kaye JA, Montine KS, McFarland L, Morrow JD, Quinn JF.

Arch Pathol Lab Med. 2001 Apr;125(4):510-2.

PMID:
11260625
[PubMed - indexed for MEDLINE]
6.

Exacerbated CSF abnormalities in younger patients with Alzheimer's disease.

Dumurgier J, Gabelle A, Vercruysse O, Bombois S, Laplanche JL, Peoc'h K, Schraen S, Sablonnière B, Pasquier F, Touchon J, Lehmann S, Hugon J, Paquet C.

Neurobiol Dis. 2013 Jun;54:486-91. doi: 10.1016/j.nbd.2013.01.023. Epub 2013 Feb 13.

PMID:
23416172
[PubMed - indexed for MEDLINE]
7.

Cross-sectional and longitudinal relationships between cerebrospinal fluid biomarkers and cognitive function in people without cognitive impairment from across the adult life span.

Li G, Millard SP, Peskind ER, Zhang J, Yu CE, Leverenz JB, Mayer C, Shofer JS, Raskind MA, Quinn JF, Galasko DR, Montine TJ.

JAMA Neurol. 2014 Jun;71(6):742-51. doi: 10.1001/jamaneurol.2014.445.

PMID:
24756381
[PubMed - indexed for MEDLINE]
8.

Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.

Thaweepoksomboon J, Senanarong V, Poungvarin N, Chakorn T, Siwasariyanon N, Washirutmangkur L, Udompunthuruk S.

J Med Assoc Thai. 2011 Feb;94 Suppl 1:S77-83.

PMID:
21721431
[PubMed - indexed for MEDLINE]
9.

Correlation of specific amyloid-β oligomers with tau in cerebrospinal fluid from cognitively normal older adults.

Handoko M, Grant M, Kuskowski M, Zahs KR, Wallin A, Blennow K, Ashe KH.

JAMA Neurol. 2013 May;70(5):594-9. doi: 10.1001/jamaneurol.2013.48.

PMID:
23479202
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Evidence for ordering of Alzheimer disease biomarkers.

Jack CR Jr, Vemuri P, Wiste HJ, Weigand SD, Aisen PS, Trojanowski JQ, Shaw LM, Bernstein MA, Petersen RC, Weiner MW, Knopman DS; Alzheimer's Disease Neuroimaging Initiative.

Arch Neurol. 2011 Dec;68(12):1526-35. doi: 10.1001/archneurol.2011.183. Epub 2011 Aug 8.

PMID:
21825215
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections.

Krut JJ, Zetterberg H, Blennow K, Cinque P, Hagberg L, Price RW, Studahl M, Gisslén M.

J Neurol. 2013 Feb;260(2):620-6. doi: 10.1007/s00415-012-6688-y. Epub 2012 Oct 9.

PMID:
23052602
[PubMed - indexed for MEDLINE]
12.

Suppression of longitudinal increase in CSF F2-isoprostanes in Alzheimer's disease.

Quinn JF, Montine KS, Moore M, Morrow JD, Kaye JA, Montine TJ.

J Alzheimers Dis. 2004 Feb;6(1):93-7.

PMID:
15004331
[PubMed - indexed for MEDLINE]
13.

Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population.

Johansson P, Mattsson N, Hansson O, Wallin A, Johansson JO, Andreasson U, Zetterberg H, Blennow K, Svensson J.

J Alzheimers Dis. 2011;24(3):537-46. doi: 10.3233/JAD-2011-101878.

PMID:
21297262
[PubMed - indexed for MEDLINE]
14.

Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings.

Petrie EC, Cross DJ, Galasko D, Schellenberg GD, Raskind MA, Peskind ER, Minoshima S.

Arch Neurol. 2009 May;66(5):632-7. doi: 10.1001/archneurol.2009.59.

PMID:
19433663
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Use of cerebrospinal fluid biomarker analysis for improving Alzheimer's disease diagnosis in a non-specialized setting.

Malnar M, Kosicek M, Bene R, Tarnik IP, Pavelin S, Babic I, Brajenovic-Milic B, Hecimovic H, Titlic M, Trkanjec Z, Demarin I, Hecimovic S.

Acta Neurobiol Exp (Wars). 2012;72(3):264-71.

PMID:
23093013
[PubMed - indexed for MEDLINE]
Free Article
16.

Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI.

Toledo JB, Xie SX, Trojanowski JQ, Shaw LM.

Acta Neuropathol. 2013 Nov;126(5):659-70. doi: 10.1007/s00401-013-1151-4. Epub 2013 Jun 29.

PMID:
23812320
[PubMed - indexed for MEDLINE]
17.

Longitudinal changes of CSF biomarkers in Alzheimer's disease.

Seppälä TT, Koivisto AM, Hartikainen P, Helisalmi S, Soininen H, Herukka SK.

J Alzheimers Dis. 2011;25(4):583-94. doi: 10.3233/JAD-2011-101911.

PMID:
21460434
[PubMed - indexed for MEDLINE]
18.

Brain ventricular volume and cerebrospinal fluid biomarkers of Alzheimer's disease.

Ott BR, Cohen RA, Gongvatana A, Okonkwo OC, Johanson CE, Stopa EG, Donahue JE, Silverberg GD, Alzheimer's Disease Neuroimaging Initiative.

J Alzheimers Dis. 2010;20(2):647-57. doi: 10.3233/JAD-2010-1406.

PMID:
20182051
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

The load of amyloid-β oligomers is decreased in the cerebrospinal fluid of Alzheimer's disease patients.

Sancesario GM, Cencioni MT, Esposito Z, Borsellino G, Nuccetelli M, Martorana A, Battistini L, Sorge R, Spalletta G, Ferrazzoli D, Bernardi G, Bernardini S, Sancesario G.

J Alzheimers Dis. 2012;31(4):865-78. doi: 10.3233/JAD-2012-120211.

PMID:
22717612
[PubMed - indexed for MEDLINE]
20.

Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.

Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM.

Arch Neurol. 2007 Mar;64(3):343-9. Epub 2007 Jan 8.

PMID:
17210801
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk